Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOLIA Study of Ismigen in children with allergic asthma
2013-000737-12Phase 3Completed
- Sponsor
- Lallemand Pharma
- Start
- Jun 2013
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma and allergic asthma comparing Ismigen add-on with Placebo add-on (2 arms). Primary endpoint: Mean ACT/P-ACT score at 3 months. Started Jun 2013; status: completed.
02
Drugs
polyvalent mechanical bacterial lysate
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on 2013-000737-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000737-12.